GSAJX
Price
$20.57
Change
+$0.24 (+1.18%)
Updated
Jun 2 closing price
Net Assets
455.98M
VEXRX
Price
$123.03
Change
+$0.62 (+0.51%)
Updated
Jun 2 closing price
Net Assets
21.76B
Interact to see
Advertisement

GSAJX vs VEXRX

Header iconGSAJX vs VEXRX Comparison
Open Charts GSAJX vs VEXRXBanner chart's image
GSAJX vs VEXRX Comparison Chart in %
View a ticker or compare two or three
VS
GSAJX vs. VEXRX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSAJX is a Buy and VEXRX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VEXRX has more cash in the bank: 21.8B vs. GSAJX (456M). VEXRX pays higher dividends than GSAJX: VEXRX (0.49) vs GSAJX (0.00). GSAJX was incepted earlier than VEXRX: GSAJX (7 years) vs VEXRX (25 years). GSAJX (1.04) is less costly to investors than VEXRX (0.28). GSAJX is a more actively managed with annual turnover of: 73.00 vs. VEXRX (51.00). VEXRX has a lower initial minimum investment than GSAJX: VEXRX (50000) vs GSAJX (1000000). GSAJX annual gain was more profitable for investors over the last year : 33.66 vs. VEXRX (21.14). GSAJX return over 5 years is better than : 30.40 vs. VEXRX (-5.81).
GSAJXVEXRXGSAJX / VEXRX
Total Expense Ratio0.910.28325%
Annual Report Gross Expense Ratio1.040.28371%
Fund Existence7 years25 years-
Gain YTD20.01214.734136%
Front LoadN/AN/A-
Min. Initial Investment1000000500002,000%
Min. Initial Investment IRAN/AN/A-
Net Assets456M21.8B2%
Annual Yield % from dividends0.000.49-
Returns for 1 year33.6621.14159%
Returns for 3 years73.4631.90230%
Returns for 5 years30.40-5.81-524%
Returns for 10 yearsN/A60.04-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TXO13.500.40
+3.05%
TXO Partners LP
YMT1.10-0.01
-0.90%
Yimutian Inc.
ILMN162.55-1.85
-1.13%
Illumina
DLO11.73-0.29
-2.41%
DLocal Limited
CRDL1.16-0.06
-4.92%
Cardiol Therapeutics